Business Context and Reporting Period
Company: Anteris Technologies Global Corp.
Filing Type: Form 8-K (Current Report)
Date: March 21, 2025
Context: The Company, an emerging growth company incorporated in Delaware, filed this report to disclose a Regulation FD announcement regarding clinical outcomes for its DurAVR Transcatheter Heart Valve (THV). The announcement was originally lodged with the Australian Securities Exchange (ASX).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of a specific corporate event rather than a periodic financial report.
Material Changes
Clinical Milestone: The Company reported one-year patient outcomes for its DurAVR THV. Specific clinical data points are contained in the attached Exhibit 99.1 (ASX Announcement) and are not detailed within the body of this 8-K text.
Guidance, Outlook, and Risks
Management Commentary: The filing serves to disseminate the ASX announcement to U.S. investors. No forward-looking guidance, financial outlook, or specific risk factors were detailed in the text of this report.
Legal Disclaimer: The information is furnished and not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (ASX Announcement) for specific one-year patient outcome data for DurAVR THV.
- Verify the Company's status as an Emerging Growth Company and its implications for financial reporting standards.
- Confirm the trading symbol AVR on the Nasdaq Global Market for current stock performance relative to this news.
- Check subsequent filings to see if this clinical data is incorporated by reference into future 10-Q or 10-K reports.